A Phase 1 Study of VG-3927 in Healthy Adults and Patients With Alzheimer's Disease

PHASE1CompletedINTERVENTIONAL

Enrollment

115

Participants

Timeline

Start Date

September 22, 2023

Primary Completion Date

January 10, 2025

Study Completion Date

January 10, 2025

Conditions

HealthyAlzheimer Disease

Interventions

DRUG

VG-3927

Dose Escalation

DRUG

Placebo

Dose Escalation

DRUG

VG-3927

One Dose Level

Trial Locations (3)

K2 Medical Research, Maitland

Clinical Pharmacology of Miami, Miami

Nucleus Network, Melbourne

All Listed Sponsors

lead

Vigil Neuroscience, Inc.

INDUSTRY

NCT06343636 - A Phase 1 Study of VG-3927 in Healthy Adults and Patients With Alzheimer's Disease | Biotech Hunter | Biotech Hunter